Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

2014464 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 15, Issue 6, pp. 569-579

Field-Weighted Citation Impact: 26.25